首页> 美国卫生研究院文献>Disease Markers >Assessment of Sialic Acid Diversity in Cancer- and Non-Cancer Related CA125 Antigen Using Sialic Acid-Binding Ig-Like Lectins (Siglecs)
【2h】

Assessment of Sialic Acid Diversity in Cancer- and Non-Cancer Related CA125 Antigen Using Sialic Acid-Binding Ig-Like Lectins (Siglecs)

机译:使用唾液酸结合的Ig样凝集素(Siglecs)评估癌症和非癌症相关CA125抗原中唾液酸多样性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study was aimed at obtaining insight into the diversity of sialic acids in cancer- and non-cancer-related CA125 antigen, tumour marker of serous ovarian cancer. Starting from available data suggesting the possible relevance of sialic acids for discriminating CA125 antigens of different origin, we have employed a new experimental approach based on the use of human sialic acid-binding Ig-like lectins, Siglecs, as tools for the investigation of sialylation.Siglec−2, belonging to the group of evolutionarily conserved Siglecs, and Siglec−3, −6, −7, −9 and −10, which are CD33-like Siglecs, were probed in solid-phase binding assays with cancer-related CA125 antigens from pleural fluid of patients with ovarian carcinoma (pfCA125), the OVCAR-3 ovarian carcinoma cell line (clCA125) and a non-cancer-related CA125 antigen, i.e. pregnancy-associated pCA125 antigen.All Siglecs used showed detectable binding to pCA125 antigen. Siglec−3, Siglec−7 and Siglec−2 exhibited moderately stronger binding to pCA125 antigen than the others. In contrast to this, Siglec−2 and Siglec−3 preferentially recognized pfCA125 with greater total binding than for pCA125, whereas Siglec−9 and Siglec−10 were highly selective for clCA125.Siglecs promise to be powerful tools for discriminating CA125 of different origin and could propagate further research on other molecular markers of biomedical and diagnostic importance.
机译:本研究旨在深入了解唾液酸在癌症和非癌症相关的CA125抗原(浆液性卵巢癌的肿瘤标志物)中的多样性。从现有数据表明唾液酸可能与区分不同来源的CA125抗原有关,我们基于人唾液酸结合Ig样凝集素Siglecs作为研究唾液酸化的工具,采用了一种新的实验方法.Siglec-2,属于进化保守的Siglecs,和Siglec-3,-6,-7,-9和-10(类似于CD33的Siglecs),在与癌症相关的固相结合测定中进行了探测卵巢癌(pfCA125),OVCAR-3卵巢癌细胞系(clCA125)和与癌症无关的CA125抗原(即妊娠相关的pCA125抗原)患者的胸膜液中的CA125抗原。所有使用的Siglecs均显示可检测到的与pCA125的结合抗原。 Siglec-3,Siglec-7和Siglec-2与pCA125抗原的结合力比其他抗体强。与此相反,Siglec-2和Siglec-3优先识别具有比pCA125更大的总结合力的pfCA125,而Siglec-9和Siglec-10对clCA125的选择性高.Siglecs承诺是区分不同来源和不同来源的CA125的有力工具。可以传播对其他具有生物医学和诊断意义的分子标记物的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号